News from BERG A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 28, 2019, 06:00 ET BERG Presents First-In-Kind Data Using Its Bayesian AI-Driven Interrogative Biology® Technology To Map Underlying Biology Of Patient Responses In Advanced Solid Tumor Trial Of BPM31510

BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease...


Apr 01, 2019, 07:30 ET BERG Presents Novel Mechanism Underlying BPM 31510 in Glioblastoma and Identification of Prostate and Pancreatic Cancer Biomarkers at 2019 AACR Meeting

BERG, a biopharmaceutical company, that combines biology and technology to discover novel biology underlying disease, today announced four...


Nov 07, 2018, 18:43 ET BERG Presents Clinical Target Validation Data for the Treatment of Parkinson's Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced four abstracts...


Nov 02, 2018, 07:04 ET Berg Analytics to Present at the AMIA 2018 Annual Symposium

Berg Analytics, a division of BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases,...


Oct 25, 2018, 13:39 ET BERG Presents New Research Using AI and Multi-Omics Toward Identification of Multiple Clinical Outcome Biomarkers for Systemic Lupus Erythematosus at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...


Oct 25, 2018, 12:30 ET BERG Presents New Research Using AI and Multi-Omics Toward Identification of Multiple Clinical Outcome Biomarkers for Systemic Lupus Erythematosus at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...


Oct 19, 2018, 18:49 ET BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the...


Jun 04, 2018, 04:53 ET BERG Showcases New Clinical Data on BPM 31510 at ASCO 2018

BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today presented in a poster...


May 23, 2018, 07:34 ET BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced that the U.S....


Apr 17, 2018, 08:16 ET BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts ...


Apr 04, 2018, 02:00 ET BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient...


Jan 22, 2018, 09:00 ET BERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer

BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and...


Dec 13, 2017, 08:00 ET New Research Partnership will Leverage BERG Interrogative Biology® Platform and Identify Novel Biomarker and Targets for Diagnosis and Treatment of Alzheimer's Disease

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts General Hospital (MGH), and...


Oct 30, 2017, 09:00 ET BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance

BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza...


Oct 27, 2017, 09:00 ET BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa (EB)

BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award ...


Sep 19, 2017, 08:00 ET BERG Broadens Relationship With The Department Of Defense (DoD) Center For Prostate Disease Research With New Predictive Biomarker Test For Prostate Cancer

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the completion of clinical...


Sep 11, 2017, 09:00 ET BERG Presents Key Clinical Data at ESMO 2017 on BPM 31510 for Advanced Pancreatic Cancer Patients and BPM 31543 for Preventing Hair-Loss in Patients Treated With Chemotherapy

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced two poster presentations showing ...


Aug 28, 2017, 12:00 ET BERG Forms Research Collaboration with AstraZeneca to Identify New Therapeutic Targets to Treat Neurological Disorders such as Parkinson's Disease

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with...


May 15, 2017, 09:00 ET BERG Announces New Partnership with debra of America to Tackle Epidermolysis Bullosa-a Rare Genetic Tissue Disorder

BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced they have entered...


Apr 03, 2017, 09:00 ET BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel

BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster...


Mar 27, 2017, 11:35 ET New Data Published in Nature Medicine from Joslin Diabetes Center Demonstrates the Importance of Interrogating Human Biology

BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company's ...


Feb 15, 2017, 08:04 ET BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)

BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has...


Feb 07, 2017, 08:02 ET BERG Announces Appointment of Titus Plattel as Chief Operating Officer

BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced the appointment of ...


Jan 12, 2017, 12:00 ET BERG Enters into Multi-Year Agreement with BD for Next-Generation Analytics in Healthcare IT

BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, announced a multi-year agreement...